Novel therapies in rheumatoid arthritis: small molecules

2015 ◽  
pp. 251-266
Author(s):  
Josef S. Smolen
Keyword(s):  
Rheumatoid Arthritis ◽  
Small Molecules ◽  
Novel Therapies

Small Molecules for Rheumatoid Arthritis

2012 ◽  
Vol 12 (9) ◽  
pp. 26-27
Author(s):  
T. Rizzo ◽  
J. M. Kremer
Keyword(s):  
Rheumatoid Arthritis ◽  
Small Molecules

Safety and Efficacy of the Newer Biological Therapeutics in the Treatment of Rheumatoid Arthritis

2011 ◽  
Vol 3 ◽  
pp. CMT.S3781 ◽  
Author(s):  
Victoria Navarro-Compán ◽  
Federico Navarro-Sarabia
Keyword(s):  
Rheumatoid Arthritis ◽  
Side Effects ◽  
Small Molecules ◽  
Wide Spectrum ◽  
Certolizumab Pegol ◽  
New Drugs ◽  
Major Advance ◽  
Biological Therapies ◽  
Safety And Efficacy ◽  
Biological Therapeutics

Biological therapies have been a major advance in RA treatment. However, remission or response is not achieved in all patients. Therefore, new drugs seem necessary. Most recent trials have focused in the development of three different groups of molecules: those against commercialized targets but minimizing side effects or improving administration, others molecules against new targets, and a third group including small molecules. Some of them have been shown to be clinically efficacious and safe in RA patients, including: two new anti-TNFα therapies (golimumab and certolizumab pegol), three anti-CD (ocrelizumab, ofatumumab and a SMIP), subcutaneous abatacept, anti-IL17 therapy, tasocitinib and fostamatinib disodium. Therefore, a wide spectrum of new RA therapeutics are promising, but more studies are necessary to confirm these results.

IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS

2019 ◽  
Vol 57 (4) ◽  
pp. 400-406 ◽  
Author(s):  
E. L. Nasonov ◽  
T. V. Korotaeva ◽  
T. V. Dubinina ◽  
A. M. Lila
Keyword(s):  
Rheumatoid Arthritis ◽  
Psoriatic Arthritis ◽  
Small Molecules ◽  
Th17 Cells ◽  
Wide Spectrum ◽  
Interleukin 17 ◽  
New Horizons ◽  
Leading Role ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Recently, more attention has been given to Th17 cells, the pathological activation of which plays a leading role in the development of a wide spectrum of human immunoinflammatory diseases (IID), including rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, inflammatory bowel diseases, etc. This has served as an incentive to design new biological agents and small molecules, the main mechanism of action of which is based on blocking the pathological effects of interleukin-17 (IL-17), others are associated with the activation of Th17 cells cytokines or signaling pathways that regulate the effects of these cytokines. The review discusses current ideas about the mechanisms regulating the formation and functional activity of IL-17 family cytokines, as well as evidence for the importance of these cytokines in the pathogenesis of IID.

Sign in / Sign up

Export Citation Format

Share Document